Novel monoclonal antibody targets CD20 in relapsed NHL HemOncToday SAN DIEGO — The novel anti-CD20 monoclonal antibody obinutuzumab was linked to better response rates than rituximab in a cohort of patients with relapsed non-Hodgkin's lymphoma, according to results presented here. Laurie H. Sehn, MD, MPH, ... |
